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The low number of women in prisons (6.4% of
the prison population and 10.8% of the jail
population) obscures the disproportionate
impact of HIV infection on incarcerated
women. In fact, prevalence of HIV infection
among women is roughly two times higher
than the rate among incarcerated men, and
it's 35 times higher than the rate of HIV infec-
tion in non-incarcerated women (see graph
p.2)(1). 
Nationally in 1996, 3.5% of women inmates
were known to be HIV-infected, compared to
2.3% of men (2). The prevalence of HIV infec-
tion among incarcerated women is even high-
er in geographical regions where HIV infection
is more concentrated; for example, in
Northeastern United States prisons, 13% of
women inmates were known to be HIV-infect-
ed compared to 7.2% of men (2).
Furthermore, while the number of incarcerat-
ed HIV-infected men has stabilized, the num-
ber of incarcerated HIV-infected women is still
increasing. From 1991 to 1996, the number of
HIV-infected women prison inmates increased
an alarming 63% (1,159 in 1991 to approxi-
mately 1,897 in 1999), while the number of
HIV infected men inmates only changed from
6,150 to approximately 6,155 in the same time
frame (2).  
In some institutions, as many as one in four of
the women in the institution are HIV infected.
The diagnosis and management of HIV and
AIDS characterizes the practice of correction-
al health care in those institutions. As a result,
correctional institutions for women that have
the highest HIV prevalence rates have been
trendsetters in three realms: standardizing
correctional HIV care (MCI Framingham, MA
and York Correctional Institute in Niantic, CT)
(3), modeling peer education (Bedford Hills
Correctional Institute, Bedford Hills, NY) (4),
and evaluating discharge planning programs
(Adult Correctional Institute, RI) (5).
Why is HIV So Prevalent?
T e crimes for which women are incarcerat-
ed--most often drug use and drug-related
crimes--are usually associated with a risk of
HIV exposure. Indeed, the more often a
woman is arrested for a criminal activity, such
as sex work or drug use, the more likely she is
to have been infected with HIV, and the more
likely she is to accumulate real "prison time".
Thus, there's a tendency for HIV prevalence to
be higher among women serving prison sen-
tences than among women who are awaiting
trial and/or serving jail time (2).
Drug offenses.Drug use is linked to HIV risk.
Nearly one in three women state prison
inmates were serving time for drug offense in
1991, compared to one in five men (6).  In
many cases, sentencing for non-drug offenses
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HEPP News, a forum for correctional
problem solving, evolved out of ongoing dis-
cussions among HIV specialists based at the
Brown University AIDS Program about the
need for HIV updates designed for practition-
ers in the correctional setting. The board of
editors includes national and regional correc-
tional professionals, selected on the basis of
their experience with HIV care in the correc-
tional environment and their familiarity with
current HIV treatment. HEPP News targets
correctional administrators and HIV/AIDS
care providers including physicians, nurses,
outreach workers and case managers.
Published monthly and distributed by fax,
HEPP News provides up-to-the-moment
information on HIV treatment, efficient
approaches to administering such treat-
ments in the correctional environment,
national and international news related to
HIV in prisons and jails, and correctional
trends that impact HIV treatment. Continuing
Medical Education credits are provided by
the Brown University Office of Continuing
Medical Education to physicians who accu-
rately respond to the questions on the last
page of the newsletter; please see last page
for details.
The editorial board and contributors to
HEPP News are well aware of the critical role
prisons and jails play in the treatment and
prevention of HIV. The goal of HEPP News is
to provide reports of effective and cost-con-
scious HIV care that can truly be implement-
ed within the correctional environment. We
hope this newsletter achieves that goal.
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The proportion of inmates with HIV is much higher than
the HIV infected proportion of the general population.
T e proportion of female inmates with HIV is exceeding-
ly higher than the general population of women.
Extrapolated from the most recent data available, CDC,
1992; and BJS.
HIV Prevalence: Inmates vs. Non-Inmates
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like larceny (to support a drug habit) may
obscure the link between incarceration and
HIV risk behaviors (6). 
Sex trade and sexually transmitted disease.
In some circumstances, sex work con-
tributes to HIV risk. Many incarcerated
women have traded sex for drugs or money,
regardless of whether they were arrested or
charged with prostitution (7). These women
may have engaged in sexual activity with
multiple high-risk partners (such as intra-
venous drug users). Additionally, there is a
high prevalence of sexually transmitted dis-
eases (STDs) among incarcerated women
(8), which may physiologically increase
women's risk of HIV infection (9).
Sexual abuse. Histories of sexual abuse
put incarcerated women at increased risk of
HIV infection (10, 11). Browne and col-
leagues and a number of other researchers
found a high rate of histories of sexual
abuse among incarcerated women. In
Browne’s study 59% of a diverse sample of
women incarcerated in a large state maxi-
mum-security prison had experienced child-
hood sexual molestation (12). Childhood
sexual abuse has a particularly profound
effect on potential HIV exposure. Stevens
and colleagues, workingat the Massachusetts
Correctional Institution at Framingham, dis-
covered that women who informed
researchers of a history of childhood sexual
abuse were 4.5 times more likely to have
participated in three HIV risk behaviors (sex
work, drug use, and non-condom use) and
2.8 times more likely to be HIV infected than
women who did not report this history (10).
Implications for Clinical Care
Preliminary new data regarding gender dif-
ferences in HIV-1 viral load is currently
available. Several studies have indicated
that women may have lower viral loads than
men with similar T-cell values (16, 17), and
that women may progress to AIDS faster
than men with similar viral loads (17). Other
studies have not shown this. In addition,
viral load may be lower in individuals of color
compared to whites (16). These differences
have led some authors to consider that rec-
ommendations for treatment be re-evaluat-
ed for women. It is important to determine
whether the response to treatment differs in
women compared to men, and in people of
color compared to whites, prior to develop-
ing new treatment recommendations that
are gender or race specific. 
The management of HIV infection among
women differs quite dramatically from the
management of HIV infection among men in
two clinical areas: gynecology and obstet-
rics. Management of HIV infection in the
pregnant woman will be covered in detail in
a separate newsletter and is also briefly
addressed in the "Ask the Expert" section
this month (see p.6).
Gynecologic Disease and Management
HIV-infected incarcerated women have high
rates of cervical cytologic abnormalities,
sexually transmitted diseases and certain
gynecologic infections. A 1995 study by
Stevens and colleagues of 88 women incar-
cerated in a Massachusetts prison found
that 68% of a sample of HIV-infected
women had had at least one recent gyne-
cological infection. Candida and tri-
chomonas infections were the most com-
mon diagnoses (10).  A recent national sur-
vey of all women incarcerated in city and
county jails showed rates of syphilis,
chlamydia and gonorrhea of 35%, 27%, and
8%, respectively (8).  Because many incar-
cerated women have a history of sexual
trauma, it is important to screen for gyneco-
logic infections but the practitioner's
approach to gynecologic exam must be
careful and sensitive (see Spotlight p.5).
Gynecological care in the correctional set-
ting presents health care providers with a
critically important context for assessing and
enhancing the health of a population largely
inexperienced with primary care, and for
curbing HIV transmission. Providers have
an opportunity to:
(1) diagnose and treat gynecological infec-
tions and STDs that may be associated with
HIV infection, 
(2) reduce the spread of HIV by treating
gynecologic infections that may facilitate
HIV transmission and by discussing tools for
risk reduction with HIV-infected women, and 
(3) refer women of unknown HIV status for
HIV testing upon diagnosis of associated
gynecological infections and STDs. 
Management of HPV and Cervical
Cytologic Abnormalities in the
Correctional Setting
The correctional HIV provider should be
aware of the association between HIV,
human papilloma virus, and abnormal cervi-
cal cytology. The management of abnormal
Pap smears in the correctional setting may
need to be more vigilant as this population
of women has had limited medical care prior
to incarceration and may also have little
access after release (see Heppigram p.7).
Therefore, a more proactive approach may
be necessary for HIV-infected women pris-
oners compared to women in community
settings who otherwise engage in routine
primary care. 
Women infected with HIV have higher rates
of human papilloma virus (HPV) expression
in cervical secretions and a higher preva-
lence of cervical cytologic abnormalities
than do HIV uninfected women (21). A
recent study by Conley and colleagues
demonstrated that the incidence of HPV-
a sociated vulvovaginal lesions was 16
times greater in HIV-infected women com-
pared to HIV-uninfected women (22). In
addition, immunosuppression has been
associated with increased pathological con-
sequences of (HPV) infection, including
i vasive cervical cancer (21). 
Routine Pap Smears
After two normal pap smears during the first
year, clinical guidelines for screening for
cervical cytologic abnormalities, as outlined
by the CDC, include performing Pap smears
annually for all HIV-infected women. Some
clinicians perform Pap smears more fre-
quently (on a six-month basis) if the CD4
count is less than 400/mm3. These clinical
guidelines may need to be modified as indi-
cated for individual patients. For example, a
provider may decide not to perform Pap
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States with the highest HIV prevalence rate include NY(20.5%), NJ (9.0%), MA(9.1%), CT(9.7), and FL(6.8%).
In those states with voluntary testing, (all but Michigan and Georgia) the prevalence rates may actually be higher
than those shown here, due to the reluctance of HIV infected individuals to come forward to be identified as HIV
seropositive in the correctional setting. Maruschak L. HIV in prisons and jails, 1996. Bureau of Justice Statistics.
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Dear Colleagues and friends, 
Welcome to the June Issue of HEPP News. As many of you know, this month's topic (the treatment of HIV infect-
ed incarcerated women) is near and dear to my heart because of my work running the ID clinic at MCI
Framingham in Massachusetts from 1992 until 1996, followed by an 18 month "stint" with Rick Altice in the HIV
clinic at the York Correctional Institution for Women in Niantic, CT. Since this issue is one of two that we have
planned on the topic of HIV care for incarcerated women, it does not discuss the treatment of sexually trans-
mitted diseases nor does it give detailed information on the treatment of pregnant HIV infected women. These
topics will be covered in future issues. 
The statistics provided in the main article in this issue are probably familiar to many of you. Women are much
less likely to be incarcerated than men, so the total number of HIV infected women in prison is much lower than
the total number of HIV infected men. However, incarcerated women, as a population, are disproportionately
affected by HIV. The reasons for the high prevalence of HIV infection among women inmates are discussed in
the main article, along with some guidelines for their care. Our HEPPigram provides a guideline to the treatment
of abnormal Pap smears, and Dr. Becky Stephenson, from the University of North Carolina (Chapel Hill), who
provides HIV care for women in the NC DOC, addresses some difficult treatment decisions in the "Ask the
Experts" section. 
Our role as HIV providers for women in the correctional setting is critically important, since we are often provid-
ing care to women who are accessing HIV care -and medical care- for the first time. Rick Altice found that two
thirds of women incarcerated in CT received their first ever antiretroviral therapy in prison. Many of our patients
will not have had a recent Pap smear, even though they fall in a high risk group for cervical cancer. Due to the
public health implications of missed diagnoses, development of HIV resistance and inadequate HIV therapy, the
correctional HIV provider must be well prepared, willing, and able to carry out his or her task. 
After reading this issue, for your continuing medical education credits, you should be able to explain the high
prevalence of HIV infection among incarcerated women, know which antiretroviral agents are appropriate for use
in treating pregnant women, know which treatment action to consider when reading a Pap smear or reviewing
colposcopy results, and recall some differences between treating HIV infected women and treating HIV infected
men. 
Many of you have written asking HEPP to address the issue of Hepatitis in the correctional setting. You'll be
pleased to hear that our local expert, Dr. Anne Spaulding, will discuss considerations for patients who are co-
infected with hepatitis B or C, and HIV, in the next issue. In the meantime, please take a moment to fill out the
HEPP News comments form. We recently compiled the responses we have received, and we're happy to see
that you like what we've done so far. You are a network of 1300 HIV providers, covering more than 800 institu-
tions in all 50 states, taking care of more than 1.6 million inmates! 
Again - welcome to HEPP News. Keep the feedback coming, and tell us how we can make HEPP News more
useful for you. 
Sincerely,  
Anne S. De Groot M.D.
L E T T E R F R O M T H E E D I T O R
S A V E T H E D A T E S
2nd Conference on Global Strategies for the
Prevention of HIV Transmission from
Mothers  to Infants
September 1-5, 1999
Montreal, Canada
Sponsored in part by: International AIDS
Society, AmFAR, Office of AIDS Research, NIH,
Canadian Assoc. for HIV Research, CDC.
Contact: Global Strategies Conference.
Phone: 514.868.1999 Web: http://www.global-
strategies.org
1999 National Conference on Women &
HIV/AIDS
October 10-12, 1999
Los Angeles, California
Contact: Gina Giovinazzi
Phone: 609.423.7222, ext. 233
Email: ggiovinazzi@talley.com
3rd Annual HCV Conference: The World and
Hepatitis C
August 21-23, 1999
Oakland, California
Topics: Sessions on Corrections Department
and Veterans Administration issues, new
research, substance abuse, harm reduction,
alternative therapies.
Contact: KREBS Convention
Management Services
Phone: 415.920.7000
Fax: 415.920.7001
Web:   http://www.hcvglobal.org
smears at the recommended frequency for a
woman who has had prior negative Pap
smears and whose HIV disease is in a very
advanced stage with opportunistic processes
which confer a poor overall clinical prognosis. 
Adequacy of Pap Smear in Screening for
Cervical Abnormalities
There are conflicting reports about the accu-
racy of the Pap smear as a screening tool for
cervical cytologic abnormalities in HIV-infect-
ed women, with some reports supporting its
efficacy (23) and other reports suggesting it
is insufficient as a diagnostic tool (24). In
response to the latter concern, Goodman
and colleagues performed a prospective
study in a correctional institution and urban
gynecology clinic in Massachusetts. The
study compared Pap test results with the
findings of colposcopy and directed biopsy.
Goodman found that Pap tests returned a
false negative result for 37% of the 102 HIV-
infected women enrolled in the study, com-
pared to 21.4% among the 82 HIV-uninfect-
ed women (24). These authors advised that
women with significantly abnormal cervical
cytology have yearly colposcopies to elimi-
nate the risk of cervical cancer. These find-
ings however do not reflect current ACOG
recommendations that support Pap smear
screening alone, with colposcopy reserved
when cytologic abnormalities are detected.
Use of Exogenous Hormones
In providing gynecologic care, it is common
to prescribe estrogens, progestin, and com-
binations of both for various conditions, in
particular, for symptoms of estrogen deple-
tion caused by natural, surgical, or premature
menopause. When HIV infection is present,
attention must be given to potential interac-
tions between exogenous hormones and HIV
drug therapies. Of particular concern are
interactions with medications that are metab-
olized in the liver, including certain antibiotics,
diphenylhydantoin, barbiturates, bronchodi-
lating agents, corticosteroids and protease
inhibitors. Another general concern is the
effect of exogenous hormones on individual
immune function. Differences in male and
female immune response are mediated by
sex hormones (in particular estrogens, prog-
esterone, and testosterone) (25). Therefore,
although testosterone replacement therapy
has become an accepted treatment for
hypogonadism and wasting in HIV-infected
men (26), providers should exercise caution
when administering less-studied female hor-
mone replacement therapy to HIV-infected
women. 
Conclusion
HIV disproportionately affects incarcerated
women. This has resulted in an increased
need for comprehensive services for HIV-
inf cted women prisoners. Correctional man-
agement of HIV-infected women must take
i o account the reasons for incarcerated
women's acute vulnerability to HIV; these
may include drug use, histories of physical
nd sexual abuse, and poverty. By testing for
HIV infection and screening for gynecologic
infections among incarcerated women, cor-
rectional health care providers can play a crit-
ical role in public health strategies for treating
and reducing the spread of infectious dis-
eases. Correctional management of HIV can
lso be viewed as an opportunity to create a
network of interconnected services that
address the needs of incarcerated HIV infect-
ed women. These services might include
physical and sexual abuse recovery pro-
grams, drug treatment, and mental health
s rvices provided in conjunction with routine
cli ical management of HIV infection.
Overall, incarceration provides a critical
opportunity for the education, diagnosis, and
medical care of HIV-infected women and
high-risk HIV seronegative women; as well
as a public health opportunity to reduce the
spread of HIV infection.
Women in Prison: The Impact of HIV
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CORRECTIONS:
Last month’s reference for the main article should have read as follows. We apologize for any inconvenience this may have caused.
Page 1:  reference 7 should be the following website:  www.cdc.gov/nchstp/hiv_aids/stats/
Page 3: reference 8 should be:  Hammett TM, Harmon P, Rhodes W.  The burden of infectious disease among inmates and releasees from correctional facilities.
Unpublished paper prepared for the National Commission on Correctional Health Care, December 1998.
Page 3: reference 10 should be reference 11, except in the inset box, "The Inside View," where it is correct.
R e s o u r c e s
S p o t l i g h t :
E x a m i n i n g  S e x u a l l y  T r a u m a t i z e d  I n c a r c e r a t e d  W o m e n
Pamela Dole has worked in corrections in both New York State at Bayview and works with nurse practitioner students from the University of Connecticut at
York Prison in Mystic,CT. Her interest in caring for sexually traumatized women grew out of listening to clients and clients needs through her work. She real-
ized some of her clients had difficulty keeping or completing appointments due to fear and anxiety from past or recent experiences of sexual victimization.
The correctional setting, according to Dole, poses an especially difficult problem for victimized women because it exaggerates their feelings of invaded pri-
vacy and loss of control. 
Dr. Dole is participating in a benchmark forensic project to decrease violence against women by educating nurses in Kimberly, South Africa. She feels fur-
ther research is necessary to fully comprehend the impact of interpersonal violence on health seeking behaviors. Dole believes the key to caring for trauma-
tized women is making the gynecologic exam a participatory process, "It can't be something done to them. . .it comes down to working from our hearts or
places of compassion." She contributed the following piece for HEPP News. 
As many as 60% of incarcerated women have histories of sexual abuse. It
is therefore appropriate to keep these histories in mind when approaching
the clinical examination of the patient in the correctional setting. Some of
the issues that interfere with medical care, as reported by sexually abused
women, include trust, authority, control, disclosure and not wishing to have
her body touched during examinations (18). Given these themes, incarcer-
ated women present with unique challenges to the health care provider, who
should not miss this opportunity for education, healing and health care
through sensitive modalities.
The first step in caring for sexually traumatized incarcerated women is to
get the inmate to keep gynecology appointments. The inmate’s desire to
remain in control and her fear of the examination will often lead her to refuse
care. As a result, gynecological care refusals need to be brought to the
attention of the medical director or nurse manager, as persistent refusals
can lead to progression of underlying disease. Refusals may be viewed as
an invitation for education, which is the first step to creating a caring and
trustful relationship with the inmate. 
If the patient is to remain within the facility for several weeks before being
reassigned, the provider should begin with an interview only and resched-
ule the examination. This approach can be extremely beneficial in increas-
ing trust and adherence over time. Inmates will feel respected for their feel-
ings while becoming acquainted with the provider in a non-threatening situ-
ation. 
The initial interview and history should include a routine OB/GYN history as
well as information about incest and child molestation, sexual assaults and
domestic violence issues. Often inmates have never been questioned
regarding sexual abuse and may initially deny these questions; however,
questioning may precipitate flashbacks after the patient has departed from
the clinic. Asking questions regarding sexual abuse during a second visit
often produces an emotional release from years of shame and secrecy,
allowing the patient to make her first disclosure of sexual victimization. It is
important to provide reassurance that anxiety about GYN exams and the
embarrassment surrounding the secrets of their childhood and/or adult sex-
ual abuse are common feelings. Whenever possible the provider should
avoid doing a pelvic examination under duress and empower the inmate to
chose a time when she is ready to participate in the Gynecological exami-
nation. This provides the possibility for increased communication and trust
while assisting the inmate to begin the healing process. 
Some inmates may not be ready to disclose their 'secrets.' Tell tale signs
nd symptoms may provide clues to the clinician. Some of these may
include histories of the following: chronic pelvic pain, dysmenorrhea, men-
orrhagia or gastrointestinal illnesses (in the absence of pathology), panic
disorders, eating problems, substance abuse, and failure to maintain good
women's health screening (19, 20). During an examination the clinician may
observe the following: stalling to disrobe, statements like 'how long will this
take?' or 'I hate these exams,’ twitchy toes during the examination, pulling
back while trying to insert the speculum, arching of the back, and dissocia-
tion from the exam itself. Should these signs occur, the provider might wish
to top the exam, allow the patient to sit up on the table and cover herself,
and hen ask whether she would be more comfortable talking about her dis-
comfort with the examination and reschedule the actual exam for another
day.
At the time of the second exam, having the patient sit on the table in her
hospital gown, ready for the exam, and discuss how she is feeling is often
helpful. At this point the provider should let the patient decide whether or not
to proceed to the examination is beneficial. Rarely does it take more than
thr e visits to complete the examination. 
Once an inmate has chosen to have the Gynecologic exam completed, it is
important to assist her in remaining relaxed and to prevent disassociation.
The most common mistake made by clinicians is to tell the inmate to relax
rather than provide her with specific methods. One method is to ask the
patient to count her respirations. The provider can also ask the patient to tell
a story, or blow bubbles, which assist her to breathe. Laughing together is
marvelous way to reduce stress. Other techniques may include guided
imagery, centering, and the use of classical music (avoid the use of music
with words). 
It is important to avoid revictimizing the inmate by a rough and insensitive
exam. During a gynecologic exam especially, women feel vulnerable and
embarrassed. Slow, gentle and supportive pelvic exams are essential. The
inmate may wish to be examined by a female health care provider. Women
who develop a rapport with their health care provider are more apt to par-
ticipate in their healthcare, thereby reducing emergent situations and long
term costs.
Pamela Dole, Correctional Gynecology Provider
Speaker’s Bureau: Agouron; Bristol-Meyers Squibb; Merck.
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RESOURCES :
GENERAL  HIV WEBSITES :
INTERNATIONAL ASSOCIATION OF PHYSICIANS IN
AIDS CARE (IAPAC)
http://www.iapac.org
JAMA (J OURNAL OF THE AMERICAN MEDICAL
ASSOCIATION) HIV/AIDS INFORMATION CENTER
http://www.ama-assn.org/special/hiv
THE BUREAU OF J USTICE STATISTICS
http://www.ojp.usdoj.gov/bjs
CDC HIV/AIDS STATISTICS
http://www.cdc.gov/nchstp/hiv_aids/stats
THE CORRECTIONS CONNECTION
http://www.corrections.com
WOMEN AND HIV WEBSITES:
HIV/AIDS TREATMENT SERVICE
http://www.hivatis.org
HEALTHSQUARE
http://www.healthsquare.com
THE BODY: WOMEN AND HIV
http://www.thebody.com/whatis/women.html 
WOMEN'S HEALTH CENTER
http://www.fwch.org
HIVWOMEN
http://www.hivwomen.com
FAMILY HEALTH INTERNATIONAL
http://www.fhi.org
MEDSCAPE : WOMEN AND HIV
http://hiv.medscape.com/medscape/hiv/clini-
calmgmt/cm.v09/public/index-cm.v09.html 
TELEPHONE  NUMBERS:
NATIONAL CLINICIANS' PEP HOTLINE:
888. 448.4911
NATIONAL HIV TELEPHONE CONSULTATION
SERVICE:
800.933.3413
ANTIRETROVIRAL PREGNANCY REGISTRY AT
PHARMA RESEARCH CORPORATION:
800. 358. 4268
A s k  T h e  E x p e r t
W h a t  W o u l d  Y o u  D o ?
One of your HIV infected patients returns to your prison clinic after a period of release to the community. She has a CD4 T cell count
of 230; a viral load of 30,000; and she has been adherent to her first antiretroviral regimen that includes AZT, 3TC, and efavirenz
since her release from the institution 3 months ago. She now tells you that she is approximately 12 weeks pregnant, and she would
like to reduce the likelihood of HIV transmission to her child as much as possible.
Becky L. Stephenson, MD
Clinical Assistant Professor, University of North Carolina
HIV Services Co-Director, NC Department of Corrections
I would use two major principles to guide my decisions for this par-
ticular scenario. In accordance with the recently updated guide-
lines for HIV-Infected Adults and Adolescents, the first would be to
provide treatment for the mother's own health and to prolong her
life. The second major principle would be to reduce transmission of
HIV to the baby. Although preventing transmission to the baby is
very important, it is inappropriate to give substandard therapy to
the mother for fear of untoward effects on the baby. 
The fact that this patient's viral load is 30,000 indicates she has
resistance to her current regimen. Her CD4 count is nearing the
definition of AIDS (CD4 count of 200), which indicates significant
immune destruction. Most experts would agree that she needs
treatment.  It is difficult to tell which, if not all, of the three anti-
retroviral agents represent resistance. It is extremely likely that she
is completely resistant to 3TC and EFV. A new regimen is likely to
be successful if most or all of the agents are changed. Thus, DDI,
D4T and nelfinavir would be my first choice. 
Unfortunately, this choice does not include AZT. AZT is the only
antiretroviral to date that has been shown to reduce perinatal
transmission of HIV. In 1994, the Pediatric AIDS Clinical Trial
Group protocol 076 showed that AZT chemoprophylaxis reduced
HIV transmission from 25% to 8%.  This involved giving AZT to the
mothers during the second or third trimester, during labor and
delivery and to the babies during the first 6 weeks of life. Because
of this data, current guidelines indicate that AZT needs to be a part
of the antiretroviral regimen of the pregnant HIV positive woman.
In situations where the choice does not include AZT, the recom-
mendation is to add AZT per the 076 protocol. Unfortunately, as
AZT and D4T are antagonistic, it is not recommended that they be
given together. Thus, my second choice would be to keep AZT and
add DDI and NFV. This would eliminate D4T and allow for the
incorporation of AZT into her antiretroviral regimen and provide her
with two new antiretrovirals.
I would also eliminate efavirenz. Efavirenz is currently listed as an
FDA category C drug. In a study of 60 pregnant monkeys given
efavirenz, three of the 20 who were delivered by caesarian section
had gross malformations: one had anencephaly and unilateral
anopthalmia, one had microophthalmia, and one had cleft palate.
The control group was negative for gross abnormalities. It is rec-
ommended that women who use efavirenz avoid pregnancy.
Because of the potential teratogenicity, I would stop efavirenz in
this pregnant woman as soon as possible and counsel about
potential birth defects and monitor with ultrasound.
Other antiretroviral options would include ritonavir and indinavir. I
would not recommend indinavir because of the potential for hyper-
ilirubinemia and renal stones which could be harmful to the baby.
Nor would I use ritonavir because of the gastrointestinal side
effects, which could worsen the hyperemesis of pregnancy.
Unfortunately, none of these antiretrovirals are very well studied in
pregnant women. 
Preventing transmission is a priority for most women and health
care providers. Most perinatal transmission is thought to occur
immediately before delivery or during breast-feeding. Thus, I would
not recommend breast-feeding. Premature rupture of membranes,
high maternal viral load, and ZDV resistance are also known to
increase perinatal transmission.  
A recent meta-analysis reported in the New England Journal of
Medicine in April of 1999 found that cesarean sections may pre-
vent perinatal transmission. The risk of HIV transmission was
found to be lower in women who underwent cesarean section
before the onset of labor and the rupture of membranes and
received zidovudine prophylaxis. There are many problems with
this study, therefore there are no current recommendations regard-
ing cesarean sections and pregnant HIV infected women. I would
ffer cesarean section if the viral load was not well controlled on
highly active antiretroviral therapy and use antiretroviral therapy as
the mainstay in reducing perinatal transmission. 
The pregnant patient's therapy should be monitored just the same
as if she were not pregnant. I would obtain a viral load 4-6 weeks
after initiating the new antiretroviral regimen to evaluate the effect
of the therapy. I would also continue checking CD4 counts and viral
loads every 3 months thereafter as I do for all my patients.
In summary, treatment of a pregnant HIV infected woman is a work
in progress. AZT should be offered to all pregnant women with HIV
and should be incorporated in their antiretroviral regimen. Even
when women have previously taken AZT, it has still been shown to
reduce transmission in their infants. I would use antiretroviral ther-
apy as the mainstay in preventing perinatal transmission. I would
only use cesarean section if there were failure to adequately sup-
press the viral load before delivery. These are difficult decisions
nd should be discussed with the pregnant women, her partner,
health care provider and her obstetrician-gynecologist. If the child
is HIV negative, the children will need follow-up since the effects of
antiretrovirals exposure are unknown in adolescence or even
ad lthood. I would also register the mother in the pregnancy reg-
istry to record safety data of antiretrovirals in pregnancy
(Pregnancy Registry: 800.358.4268).
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Report From the 8th Canadian
Conference on HIV/AIDS Research,
Victoria, B.C.
Researchers from the Toronto Hospital
Immunodeficiency Clinic assessed the risk of
elevated triglyceride (TG), cholesterol and
glucose levels in HIV-positive patients taking
protease inhibitors. The research said
increased lipid levels were observed with all
PIs. They found that subjects taking protease
inhibitors had significantly higher TG and
cholesterol levels than those taking other
antiretrovirals.Ritonavir andritonavir/saquinavir
showed the most significant increases in cho-
lesterol and TG levels. The second highest
lipid increase was seen with nelfinavir, fol-
lowed by indinavir, and saquinavir. Blood glu-
cose levels were also higher in the PI-treat-
edgroup than in those treated with other anti-
retrovirals. (Abstract B213)
Number of U.S. Inmates Increases Again
At midyear 1998, Federal and State prison
authorities and local jails held in their custody
668 persons per 100,000 U.S. residents.  On
June 30, 1998, 1,277,866 prisoners were
under Federal and State jurisdictions, an
increase of 4.8% since midyear 1997.
Approximately 452 per 100,000 U.S. resi-
dents were incarcerated in a State or Federal
prison, up from 303 per 100,000 residents in
1990. Compared to U.S. resident population,
the incarceration rate was about 16 times
higher for men than for women.Source: Prison
and Jail Inmates at Midyear 1998, a Bureau of
Justice Statistics Bulletin. Available at:
http://www.ojp.usdoj.gov/bjs/
HIV Virus Projected to Persist for
Decades Despite HAART
Johns Hopkins University researchers have
found that HIV can hide in viral reservoirs for
up to 60 years, quashing hopes of eradicating
the virus with existing treatments. Calling the
finding "far from bleak," National Institute for
Allergy and Infectious Diseases Director Dr.
Anthony Fauci said, "I want to caution people
not to think it's such horrible news and that
these drugs [antiretroviral therapy] don't do
a y good.  They are still extremely important
in improving the quality and duration of life"
(Finzi D et al.  Nature Medicine, May 1999;
5(5):512-517. Baltimore Sun, 4/27)
News Flashes 
HEPPigram A feature of HEPPNews providing concise solutions to correctional HIV-related problems.
Treatment UpdatesA new feature of HEPP News
Updated Clinical Guidelines
Available Online
The AIDS Treatment Information Service website
has posted the most recent version of the
"Guidelines for Use of Antiretroviral Agents in HIV-
Infected Adults and Adolescents," with new infor-
mation on all antiretroviral agents, including the
recently approved reverse transcriptase inhibitor
abacavir, or Ziagen.  To view  them, go to
http://www.hivatis.org/ 
Amprenavir - New Protease
Inhibitor on the (Cell) Block
In April, the FDA approved the protease inhibitor
amprenavir (Agenerase, Glaxo-Wellcome) for use in
treating HIV infection. Amprenavir's approval comes 2
years after the release of nelfinavir and may be the last
available drug of this class for the next few of years.
The drug in combination with other antiretrovirals has
b en studied in over 700 patients, both antiretroviral
naïve and experienced, and has provided viral load
reductions and CD4 cell count increases that are com-
parable to other protease inhibitor regimens.
The dose of amprenavir is 1200 mg twice a day. Since
the current capsules contain 150 mg each, dosing
requires 8 pills BID. Amprenavir can be taken with or
without food, but it should not be taken with a high-fat
meal because the fat content may decrease drug
absorption. The most frequently reported adverse
events among patients in clinical trials of amprenavir
were nausea (15%), diarrhea (14%), vomiting (5%),
and rash (11%).  Severe and life-threatening skin reac-
tions, including Stevens-Johnson syndrome, have
occurred in patients treated with amprenavir. Acute
hemolytic anemia, diabetes melitus and hyperglycemia
may also be associated with amprenavir.
Given the overlap of amprenavir and other protease
inhibitors resistance patterns this agent may not prove
to be a reliable component of salvage therapies for
patients failing other protease inhibitor regimens.
However, for some patients with few salvage options,
amprenavir may well be worth considering. Whether
amprenavir can effectively compete with other pro-
tease inhibitors as initial therapy remains to be seen. 
(Contributed by David Alan Wohl, MD, Speaker’s
Bureau: Roche, Bristol Myers Squibb, Glaxo, and
Roxane.) 
Cervical
cytology
performed Q
6-12 months
Within
normal limits
Benign cellular
changes
Unsatisfactory for
evaluation
Repeat now
Repeat annually
Repeat Q 6 months if there is a history of
anogenital HPV infection or SIL
Infection or
inflammatory
Treat according
to diagnosis
Repeat cytology in
3 months
Epithelial cell
abnormalities
1. Atypical squamous cells of
undetermined significance
(ASCUS)
2. LowGrade squamous
intraepithelial lesions (LGSIL)
3. High grade squamous
intraepithelial lesions (HGSIL)
Colposcopy
with directed
biopsy
dysplasia
No dysplasia
1.  Gynecology
consultation
2.  Ablative therapy
Repeat cervical
cytology in 6
months
Approach to Cervical Cytologic Evaluation for HIV-Infected Women:
The increase in development and progression of
cervical dysplasia is believed to occur because HIV-
infected women have decreased tumor surveillance
capacity because of their altered immunoregulatory
mechanisms. Studies of the overall incidence of
cervical cancer in HIV infected patients with squa-
mous cell lesions are on going (personal communi-
cation, S. Cu-Uvin).
In the prison or jail setting, a more interventional
approach is favored because 
1) inmates do not necessarily remain in the correc-
tional environment for prolonged periods; 2) should
inmates be released to the community they may not
be living in stable circumstances, and 3) it is unlike-
ly that the individual will have her gynecologic
issues addressed in the community while facing
issues such as securing stable housing, meeting
basic needs, providing for children and addressing
issue related to treatment of her HIV/AIDS.  Thus
for women in the correctional setting who have
squamous cell lesions, it is prudent to go directly to
colposcopy with directed biopsy and offer treatment
if necessary.
Source: Altice, F.L. “Management of HIV Infection in
Correctional Settings.” Clinical Practice in Medicine.
Ed. M. Pusis. St. Louis, IL: D.O. Mosby, 1998. Ch.
15.
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Antiretroviral Agent
FDA
Pregnancy
Category*
Placental
Passage
Long-term
animal
carcinogenicity
studies
Rodent
Teratogen
Nucleoside Analog Reverse Transcriptase Inhibitors
Abacavir (ABC, C Yes (rats) Not completed +
Didanosine (ddI, Videx) B Yes (human) Negative (no
tumors, lifetime
rodent study)
-
Lamivudine (3TC, Epivir) C Yes (human) Negative (no
tumors, lifetime
rodent study)
-
Stavudine (d4T, Zerit) C Yes (rhesus) Not completed -
Zalcitabine (ddC, Hivid) C Yes (rhesus) Positive
(rodent, thymic
lymphomas)
+
Zidovudine (AZT, Retrovir) C Yes (human) Positive (rodent,
noninvasive
vaginal,
epithelial tumors)
+
Non-nucleoside Reverse Transcriptase Inhibitors
Delavirdine (DLV, Rescriptor) C Unknown Not completed +
Nevirapine ( NVP, Viramune) C Yes (human) Not completed -
Efavirenz (EFV, Sustiva) C Yes
(cynomolgus)
Not completed +
Protease Inhibitors
Indinavir (IDV, Crixivan) C Yes (rats) Not completed -
Nelfinavir (NFV, Viracept) B Unknown Not completed -
Ritonavir (RTV, Norvir) B Yes (rats) Not completed -
Saquinavir (SQV, Invirase/Fortuvase) B Yes
(rats/rabbits)
Not completed -
These recommendations should be followed
with the consultation of an expert on a case-by-
case basis.  Antiretroviral therapies are under
constant study, so primary sources should be
consulted, as the information provided above
may become quickly outdated.  (Sources:
Merigan T, Bartlett J, Bolognesi D.  Textbook of
AIDS  Medicine, Second Edition. Williams and
Wilkins. Baltimore MD. 1999. Updated from the
HIV/AIDS Treatment Information Service web-
site:  http://www.hivatis.org and the Antiretroviral
Pregnancy Registry at Pharma Research
Corporation, 800.358.4268)
This treatment is best done in collaboration with
an HIV provider who has experience in this area,
as information on drug treatment changes fre-
quently.
* US Food and Drug Administration pregnancy
categories are:
A: Adequate and well-controlled studies of preg-
nant women fail to demonstrate a risk to the fetus
during the first trimester of pregnancy (with no evi-
dence of risk during later trimesters).
B:  Animal reproduction studies fail to demonstrate
a risk to the fetus, and adequate, but well-con-
trolled studies of pregnant women have not been
conducted.  
C:  Safety in human pregnancy has not been
determined; animal studies are either positive for
fetal risk  or have not been conducted, and the
drug should not be used unless the potential ben-
efit outweighs the potential risk to the fetus.
D: Positive evidence of human fetal risk is based
on adverse reaction data from investigational or
marketing experiences, but the potential benefits
from the use of the drug in pregnant women may
be acceptable despite its potential risks.
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Recommended Antiretroviral Agents for the Treatment of HIV-Infected Pregnant Women
Self-Assessment Test for Continuing Medical Education Credit
Brown University School of Medicine designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s
Recognition Award.  To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each
of the questions. A minimum of 70% of the questions must be answered correctly.  This activity is eligible for CME credit through August
15, 1999.  The estimated time for completion of this activity is one hour and there is no fee for participation in this activity.
1. For HIV infected women, cervical cytology should be repeated six
months after the first test for all of the following cases EXCEPT:
a) Test reveals atypical squamous cells of undetermined signifi-
cance.  Colposcopy reveals no dysplasia.
b) Test reveals high grade squamous intraepithelial lesions.  
Colposcopy reveals no dysplasia.
c) Test reveals benign cellular changes, and infection or inflam-
mation.
d) Patient has a history of anogenital HPV infection or SIL. 
Cervical cytology test results are within normal limits.
2. Which of the following medicines CANNOT be used for pregnant HIV
infected women?
a) zidovudine (ZDV,AZT)
b) efavirenz (EFZ)
c) nevirapine (NVP)
d) didanosine (DDI)
e) saquinavir (SQV)
3. Which of the following statements about HIV infected women and cer-
vical cytologic abnormalities is FALSE?
a) According to a 1997 NEJM article, HIV infected women have 
particularly high rates of cervical cytologic abnormalities, sexu-
ally transmitted diseases and certain gynecologic infections.
b) The management of abnormal Pap smears in the correctional 
setting may need to be more vigilant as this population of 
women has had little medical care prior to incarceration and 
may also have little access after release.
c) According to the CDC, pap smears should be preformed annu-
ally for all HIV-infected women.
d) HIV un-infected women have higher rates of HPV expression 
in cervical secretions and higher prevalence of cervical cytolog-
ic abnormalities than do HIV infected women.
e) None of the above.
4. Which of the following characteristics put incarcerated womenat higher
risk for HIV?
a) involvement in sex trade 
b) drug use
c) history of childhood sexual abuse
d) a and b
e) all of the above
f) none of the above
5. True or False?  Some studies have found that more than half of a pop-
ulation of incarcerated women were sexually abused as children, which
may lead to HIV risky behaviors as adults.
True False
6. Which of the following is TRUE about treating an HIV infected woman?
a) Practitioners should watch for interactions between the 
patient's antiretroviral therapy and diphenylhydantoin.
b) Testosterone replacement therapy has become an accepted 
treatment for wasting in HIV infected women.
c) Differences in male and female immune response to HIV are 
mediated in part by sex hormones, therefore providers should 
exercise caution when administering female hormone replace
ment therapy to HIV-infected women.
d) a and c.
e) all of the above
BROWN UNIVERSITY SCHOOL OF MEDICINE • OFFICE OF CONTINUING MEDICAL EDUCATION • BOX G-A2 • PROVIDENCE, RI 02912
The Brown University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME)t  sponsor contin-
uing medical education activities for physicians.  This activity has been planned and implemented in accordance with the Essentials and Standards
of the ACCME.
The use of the Brown University School of Medicine name implies review of the educational format and material only.  The opinions, recommenda-
tions and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the
Brown University School of Medicine.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660
Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
main article 5  4  3  2  1   5  4  3  2  1   
case study 5  4  3  2  1   5  4  3  2  1   
HEPPigram 5  4  3  2  1   5  4  3  2  1   
updates 5  4  3  2  1   5  4  3  2  1   
save the date 5  4  3  2  1   5  4  3  2  1   
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPPNews be made more useful to you?
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